Melanotan II
Melanocortin agonist for pigmentation and libido; significant safety concerns.
What it is
Melanotan II (MT-II) is a synthetic melanocortin receptor agonist with broad activity at MC1R, MC3R, MC4R, and MC5R subtypes. It was originally developed at the University of Arizona in the 1990s as a research tool to study melanocortin signaling. The compound was investigated for skin pigmentation enhancement (via MC1R activation) and sexual dysfunction (via MC4R/MC3R activation).
Melanotan II has never been approved by the FDA or any major regulatory body for human use. The compound has been associated with significant safety concerns and has been the subject of regulatory warnings in multiple countries due to unsupervised consumer use.
Mechanism of action
Broad melanocortin receptor agonism produces:
- MC1R activation: increases melanin production in melanocytes, leading to skin darkening
- MC3R/MC4R activation: central effects on appetite, sexual response, and energy metabolism
- MC5R activation: effects on sebaceous gland function
The non-selective receptor binding contributes to the broad and sometimes unpredictable effects.
Why we do not prescribe Melanotan II
The Tide does not prescribe Melanotan II for several reasons of significant clinical concern:
- Atypical melanocyte changes: case reports document new melanocytic lesions, atypical mole formation, and changes in existing nevi following Melanotan II use. Some cases have progressed to malignant melanoma. This is an unacceptable risk.
- Safer alternatives exist: Bremelanotide (PT-141) is FDA-approved with a more focused MC3R/MC4R activity profile and substantially better safety data, providing the sexual response benefits without the broad melanocortin activation.
- Contaminated supply: consumer-sourced Melanotan II has been found to vary substantially in purity and identity, with documented cases of toxic contamination.
- Severe nausea and other side effects are common at effective doses
- No legitimate clinical pathway: the compound has not received approval for any indication and lacks the clinical infrastructure (dosing guidance, monitoring protocols, safety data) that supports responsible prescribing.
Patients seeking the sexual response benefits associated with melanocortin agonism are appropriately served by Bremelanotide. Patients seeking skin pigmentation effects should not pursue Melanotan II — sun protection and dermatologic care are the appropriate pathways for skin concerns.
Significant safety concerns
- Atypical pigmented lesions and possible melanoma risk
- Severe nausea and vomiting
- Significant blood pressure changes
- Priapism in men
- Generalized hyperpigmentation
- Loss of body hair pigmentation